Lv2
110 积分 2025-02-10 加入
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
3个月前
已完结
Recent nanotechnological aspects and molecular targeting strategies for lung cancer therapy
4个月前
已完结
Taletrectinib (Ibtrozi) - another kinase inhibitor for non-small cell lung cancer (NSCLC)
6个月前
已关闭
Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study
6个月前
已完结
Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo
6个月前
已完结
Discovery of flavonoid-containing compound Lupalbigenin as anti-NSCLC cancer agents via suppression of EGFR and ERK1/2 pathway
6个月前
已完结
皖公网安备34019202002308
